Eloxx Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• Eloxx Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2026 and provided a business update in a press release dated August 11, 2026. The company filed a Current Report on Form 8-K (Item 2.02) furnishing that press release (Exhibit 99.1).
• The 8-K states the press release is furnished — not “filed” — for purposes of Section 18 of the Exchange Act (standard disclosure language about liability and incorporation).

Key Details

• Filing date: August 11, 2026; reporting period: quarter ended June 30, 2026.
• Press release announcing the quarterly results and business update is attached as Exhibit 99.1 to the 8-K.
• The filing includes the Cover Page Interactive Data File in Inline XBRL format (Exhibit 104).

Why It Matters

• Quarterly results and the company’s business update can affect investor views on revenue, R&D spending, cash runway, and clinical program progress—key metrics for a clinical-stage biopharma like Eloxx. Retail investors should read the attached press release for the actual financial figures (revenue, net income/loss, cash balance) and any operational or pipeline milestones mentioned.
• Because the press release is furnished (not “filed”), the company includes standard liability language; investors should rely on the primary filings (10-Q/10-K) for formally filed financial statements and disclosures.

Read the Exhibit 99.1 press release referenced in the 8-K to see the specific financial numbers and business updates.